Bristol-Myers Squibb and AstraZeneca announced the published results from their Phase 2b trial of dapagliflozin for treatment-naïve type 2 diabetes patients.  The results of this randomized, double-blind, placebo-controlled, parallel-group study of 389 patients (ages 18-79) demonstrated that dapagliflozin produced clinically meaningful reductions across all key glycemic measures studied [glycosylated hemoglobin level (HbA1c), fasting plasma glucose (FPG), and postprandial plasma glucose (PPG)], compared to placebo.

Dapagliflozin is a novel, selective, sodium glucose co-transporter2 (SGLT2) inhibitor that limits the amount of glucose that is reabsorbed and retained in the body, thereby leading to the excretion of glucose in the urine.

For more information visit www.bms.com or www.astrazeneca.com.